Abstract
Over the last few years, deaths caused by multidrug-resistant bacteria (MDRB) have been rising at an alarming rate, therefore, the search for new compounds capable of dealing with these microorganisms is highly important. Amongst the compounds with potential for new therapies, there are the peptidoglycan recognition proteins (PGLYRPs) and antimicrobial peptides (AMPs). PGLYRPs recognize c…